Recursion Pharmaceuticals, Inc. RXRX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s accrued liabilities, current?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued liabilities, current of $54.21M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued liabilities, current changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued liabilities, current decreased by 4.6% year-over-year, from $56.8M to $54.21M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accrued liabilities, current?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s accrued liabilities, current has grown at a 46.3% compound annual growth rate (CAGR), from $10.49M to $70.23M.